# US 2025/0084152 A1 · Compositions For and Methods of Treating Influenza

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084152 A1
- Document ID: US20250084152A1
- Status: Published application
- Kind: A1
- Application number: 18/883,669
- Filed: 2024-09-12
- Published: 2025-03-13
- Earliest claimed: 2023-09-12
- Applicants: Duke University; President and Fellows of Harvard College
- Inventors: Garnett Kelsoe; Joel Finney; Stephen Harrison
- Web page: https://patentgrep.com/patent/US20250084152A1

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- A61K 2039/505: {comprising antibodies}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are binding molecules and/or antibodies targeting a universal influenza antigen and methods of using the same to treat a subject having an influenza infection and to minimize the progression of an influenza infection in a subject.

## Claims

### Claim 1

A binding molecule capable of specifically binding to postfusion hemagglutinin (HA),
wherein the binding molecule binds to the stem region of HA; and
wherein the stem region of HA comprises an epitope comprises a β-hairpin.

### Claim 2 (depends on 1)

The binding molecule of claim 1, wherein the epitope comprises the sequence set forth in SEQ ID NO:191.

### Claim 3 (depends on 1)

The binding molecule of claim 1, comprising:
(i) a variable light chain region (VL) comprising 3 complementarity determining regions (CDRs), and
(ii) a variable heavy chain region (VH) comprising 3 CDRs and a constant heavy chain region.

### Claim 4 (depends on 3)

The binding molecule of claim 3, wherein the VH comprises a sequence having at least 80% identity to the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:16.

### Claim 5 (depends on 3)

The binding molecule of claim 3, wherein the VL comprises a sequence having at least 80% identity to the sequence set forth in any one of SEQ ID NO:17-SEQ ID NO:28.

### Claim 6 (depends on 4)

The binding molecule of claim 4, wherein the VH comprises a sequence having at least 80% identity to the sequence set forth in SEQ ID NO:05 or SEQ ID NO:06.

### Claim 7 (depends on 5)

The binding molecule of claim 5, wherein the VL comprises a sequence having at least 80% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18.

### Claim 8 (depends on 3)

The binding molecule of claim 3, wherein the VL comprises at least one CDR having the sequence set forth in any one of SEQ ID NO:64-SEQ ID NO:69; and wherein the VH comprises at least one CDR having the sequence set forth in any one of SEQ ID NO:59-SEQ ID NO:63.

### Claim 9 (depends on 3)

The binding molecule of claim 3, wherein the first CDR in the VL comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65; the second CDR in the VL comprises a sequence having at least 80% identity to the sequence set forth in SEQ ID NO:66 or SEQ ID NO:67; and the third CDR in the VL comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:68 or SEQ ID NO:69.

### Claim 10 (depends on 3)

The binding molecule of claim 3, wherein the first CDR in the VH comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:59 or SEQ ID NO:60; the second CDR in the VH comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:61 or SEQ ID NO:62; and the third CDR in the VH comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:63.

### Claim 11 (depends on 3)

The binding molecule of claim 3, wherein the VL comprise at least one CDR having the sequence set forth in any one of SEQ ID NO:75-SEQ ID NO:80; and wherein the VH comprises at least one CDR having the sequence set forth in any one of SEQ ID NO:70-SEQ ID NO:74.

### Claim 12 (depends on 3)

The binding molecule of claim 3, wherein the first CDR in the VH comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:70 or SEQ ID NO:71; the second CDR in the VH can comprise a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:72 or SEQ ID NO:73; and the third CDR in the VH comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:74.

### Claim 13 (depends on 3)

The binding molecule of claim 3, wherein the first CDR in the VL comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:75 or SEQ ID NO:76; the second CDR in the VL comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:77 or SEQ ID NO:78; and the third CDR in the VL comprises a sequence having at least about 80% identity to the sequence set forth in SEQ ID NO:79 or SEQ ID NO:80.

### Claim 14 (depends on 3)

The binding molecule of claim 3, wherein the VL is encoded by IGLV2-23*01/IGLJ3*02, wherein the VL comprises about 1% to about 20% somatic mutations; and wherein the VH is encoded by IGHV1-2*02/IGHD5-12*01/IGHJ5*02, wherein the VL comprises about 1% to about 20% somatic mutations.

### Claim 15 (depends on 3)

The binding molecule of claim 3, wherein the VL is encoded by IGLV2-23*01/IGLJ3*02, wherein the VL comprises about 1% to about 20% somatic mutations; and wherein the VH is encoded by IGHV1-2*07/IGHD6-13*01/IGHJ4*02, wherein the VL comprises about 1% to about 20% somatic mutations.

### Claim 16 (depends on 1)

A pharmaceutical formulation comprising the binding molecule of claim 1.

### Claim 17 (depends on 16)

A method of treating a subject, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical formulation of claim 16.

### Claim 18 (depends on 17)

The method of claim 17, wherein following the administering step, (i) the risk of the subject's mortality is minimized and/or decreased; (ii) the subject's survival is increased and/or prolonged; (iii) the subject's quality of life is enhanced and/or improved; (iv) the likelihood of surgical intervention is reduced and/or minimized; (v) the frequency of other treatment is reduced and/or decreased; (vi) one or more subject's symptoms is relieved and/or ameliorated; (vii) the subject's risk of hospitalization is reduced and/or minimized; (viii) the need for surgical intervention is prevented and/or minimized; (ix) normal metabolism of one or more of the subject's organ systems is improved and/or restored, (x) one or more aspects of cellular homeostasis and/or cellular functionality, and/or metabolic dysregulation in one or more of the subject's affected systems is restored and/or improved, or (xi) any combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, further comprising repeating the administering to the subject of the pharmaceutical formulation.

### Claim 20 (depends on 17)

The method of claim 17, further comprising administering to the subject one or more postfusion hemagglutinin (HA) proteins, wherein the one or more proteins comprise the sequence set forth in any one of SEQ ID NO:29-SEQ ID NO:58 and SEQ ID NO:192-SEQ ID NO:218.
